(Q45746984)

English

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.

scientific article published on 14 March 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

phase III clinical trial

0 references

author name string

S Hodder

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

K Arasteh

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

J De Wet

3

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

J Gathe

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

J Gold

5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

P Kumar

6

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

L Mohapi

7

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

W Short

8

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

H Crauwels

9

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

S Vanveggel

10

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

K Boven

11

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

publication date

14 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

13

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

7

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

406-415

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Hepatotoxicity associated with nevirapine use.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Appropriate use of nevirapine for long-term therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Sex differences in antiretroviral therapy-associated intolerance and adverse events

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Better mind the gap: addressing the shortage of HIV-positive women in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.00991.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2012.00991.X

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/22416849

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45746984&oldid=798462230"